Dr. James L. Smythe

Beth Overmoyer is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Overmoyer is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Angiosarcoma, and Paget Disease of the Breast.

Dr. Lynce received her medical degree from the Universidade Nova de Lisboa, Portugal in 2004. She completed her residency in Internal Medicine and fellowship in Hematology and Medical Oncology at MedStar Washington Hospital Center/MedStar Georgetown University Hospital in Washington, DC. She was faculty at MedStar Georgetown University Hospital from 2015 to 2020 where she served as the institutional PI for Alliance and the co-PI for the National Capital Area (NCA) Minority/Underserved NCORP. In 2020, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she is a medical oncologist and clinical investigator in the Breast Oncology Center. Her research focuses on inflammatory breast cancer, triple-negative breast cancer, BRCA-associated breast cancers and novel therapies in the treatment of breast cancer. Dr. Lynce is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, Angiosarcoma, and Salpingo-Oophorectomy.

Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy.She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen. She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials.  Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others. She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Tolaney is rated as an Elite provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Triple-Negative Breast Cancer.